Capan-1 pancreatic cancer cell line (Capan-1)

Capan-1 is a well-characterized human pancreatic ductal adenocarcinoma cell line established from a liver metastasis of a 40-year-old male patient (ATCC HTB-79). It is widely utilized in oncology research as a model for studying the molecular mechanisms of pancreatic cancer progression and therapeutic resistance (Cytion). The cell line is most distinguished by its homozygous 6174delT mutation in the BRCA2 gene, which leads to the production of a truncated, non-functional protein and a subsequent defect in homologous recombination-mediated DNA repair (PubMed: 15162061). This specific deficiency renders Capan-1 cells highly sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib and talazoparib, and platinum-based chemotherapeutic agents, making it a primary model for investigating synthetic lethality (PubMed: 15897453). In addition to its BRCA2 status, Capan-1 cells harbor other hallmark mutations of pancreatic cancer, including KRAS (G12V) and TP53 mutations, and they are characterized by the loss of SMAD4 expression (AcceGen). The cells also exhibit high levels of mucin-1 (MUC1) and carcinoembryonic antigen (CEA), which are often used as biomarkers in experimental studies (PubMed: 15933831).

Other names

HTB-79CaPan-1Capan1

Not applicable as this is a cell line; however, it is a primary model for studying synthetic lethality via PARP inhibition in BRCA2-deficient backgrounds.